Clinical Use of Interferon-γ

Authors

  • Catriona H.T. Miller,

    1. Center for Cancer Research, Cancer and Inflammation Program, Laboratory of Experimental Immunology, National Cancer Institute-Frederick, Frederick, Maryland, USA
    Search for more papers by this author
  • Stephen G. Maher,

    1. Department of Surgery, Trinity Centre for Health Sciences, Trinity College Dublin, St. James's Hospital, Dublin 8, Ireland
    Search for more papers by this author
  • Howard A. Young

    1. Center for Cancer Research, Cancer and Inflammation Program, Laboratory of Experimental Immunology, National Cancer Institute-Frederick, Frederick, Maryland, USA
    Search for more papers by this author

Address for correspondence: Howard A. Young, Laboratory of Experimental Immunology, Cancer and Inflammation Program, National Cancer Institute-Frederick, Building 560 RM31-16, Frederick, MD 21702. Voice: 301-846-5700. younghow@mail.nih.gov

Abstract

Interferon gamma (IFN-γ), a pleotropic cytokine, has been shown to be important to the function of virtually all immune cells and both innate and adaptive immune responses. In 1986, early clinical trials of this cytokine began to evaluate its therapeutic potential. The initial studies focused on the tolerability and pharmacology of IFN-γ and systematically determined its antitumor and anti-infection activities. In the 20-plus years since those first trials, IFN-γ has been used in a wide variety of clinical indications, which are reviewed in this article.

Ancillary